Cancer Registry
Cancer Registry data on the IBIS Website are from the Utah Cancer Registry, a population-based cancer registry that has served the State of Utah since 1966. The Utah Cancer Registry is also one of the original members of the National Cancer
Institute's Surveillance, Epidemiology, and End Results (SEER) Program and has continuously participated in the SEER Program since 1973. More information about the Utah Cancer Registry can be found at
http://uuhsc.utah.edu/ucr/.
Rates are computed using population estimates from the Utah Governor's Office of Planning and Budget (GOPB), the U.S. Census, and ESRI. For more information about population estimates see the help page for Population Estimates
The Utah Cancer Registryis not a closed database meaning that numbers can be updated for any year. When we add new years of data to the IBIS Query System the numbers for previous years may change to reflect these updates.
Slight variations in case counts and rates may have also appear since the adoption of the International Classification of Disease for Oncology, 3rd Edition (ICD-O-3), primary site and histology codes. For more detailed information about the ICD-O-2 to ICD-O-3 conversion, please go to http://www.seer.cancer.gov/siterecode/
Rates are computed using population estimates from the Utah Governor's Office of Planning and Budget (GOPB), the U.S. Census, and ESRI. For more information about population estimates see the help page for Population Estimates
The Utah Cancer Registryis not a closed database meaning that numbers can be updated for any year. When we add new years of data to the IBIS Query System the numbers for previous years may change to reflect these updates.
Slight variations in case counts and rates may have also appear since the adoption of the International Classification of Disease for Oncology, 3rd Edition (ICD-O-3), primary site and histology codes. For more detailed information about the ICD-O-2 to ICD-O-3 conversion, please go to http://www.seer.cancer.gov/siterecode/
Primary Cancer Site/Type Categories and Definitions
(last updated December 2005) (source: Utah Cancer Registry)Primary Cancer Site/Type 1 = Standard categories
Primary Cancer Site/Type 2 = Individual sites
| ICDO-3 Sites/Types -INCLUDED- | ICDO-3 Sites/Types -EXCLUDED- | |||||
|---|---|---|---|---|---|---|
| Primary Cancer Site/Type 1 | Primary Cancer Site/Type 2 | ICD-O-3 Codes | Excluded Sites/Types | Histologies | ||
| Code | Sites/Types | Code | Sites/Types | |||
| 01 | Oral cavity and pharynx | 0101 | Lip | C00.0-C00.9 | Lymphomas | M9590-9989 |
| 0102 | Tongue | C01.9-C02.9 | Lymphomas | M9590-9989 | ||
| 0103 | Salivary glands | C07.9-C08.9 | Lymphomas | M9590-9989 | ||
| 0104 | Floor of mouth | C04.0-C04.9 | Lymphomas | M9590-9989 | ||
| 0105 | Gum and other mouth | C03.0-C03.9, C05.0-C05.9, C06.0-C06.9 | Lymphomas | M9590-9989 | ||
| 0106 | Nasopharynx | C11.0-C11.9 | Lymphomas | M9590-9989 | ||
| 0107 | Tonsil | C09.0-C09.9 | Lymphomas | M9590-9989 | ||
| 0108 | Oropharynx | C10.0-C10.9 | Lymphomas | M9590-9989 | ||
| 0109 | Hypopharynx | C12.9, C13.0-C13.9, C14.1 | Lymphomas | M9590-9989 | ||
| 0110 | Other oral cavity and pharynx | C14.0, C14.2-C14.8 | Lymphomas | M9590-9989 | ||
| 02 | Esophagus | 0200 | Esophagus | C15.0-C15.9 | Lymphomas | M9590-9989 |
| 03 | Stomach | 0300 | Stomach | C16.0-C16.9 | Lymphomas | M9590-9989 |
| 04 | Small intestine | 0400 | Small intestine | C17.0-C17.9 | Lymphomas | M9590-9989 |
| 05 | Colon (excluding rectum) | 0500 | Cecum | C18.0 | Lymphomas | M9590-9989 |
| Appendix | C18.1 | Lymphomas | M9590-9989 | |||
| Ascending colon | C18.2 | Lymphomas | M9590-9989 | |||
| Hepatic flexure | C18.3 | Lymphomas | M9590-9989 | |||
| Transverse colon | C18.4 | Lymphomas | M9590-9989 | |||
| Splenic flexure | C18.5 | Lymphomas | M9590-9989 | |||
| Descending colon | C18.6 | Lymphomas | M9590-9989 | |||
| Sigmoid colon | C18.7 | Lymphomas | M9590-9989 | |||
| Large intestine, NOS | C18.8-C18.9, C26.0 | Lymphomas | M9590-9989 | |||
| 06 | Rectum and rectosigmoid junction | 0600 | Rectosigmoid junction | C19.9 | Lymphomas | M9590-9989 |
| Rectum | C20.9 | Lymphomas | M9590-9989 | |||
| 07 | Anus, anal canal, and anorectum | 0700 | Anus, anal canal, and anorectum | C21.0-C21.2, C21.8 | Lymphomas | M9590-9989 |
| 08 | Liver and intrahepatic bile duct | 0801 | Liver | C22.0 | Lymphomas | M9590-9989 |
| 0802 | Intrahepatic bile duct | C22.1 | Lymphomas | M9590-9989 | ||
| 09 | Gallbladder and biliary ducts | 0901 | Gallbladder | C23.9 | Lymphomas | M9590-9989 |
| 0902 | Other biliary ducts | C24.0-C24.9 | Lymphomas | M9590-9989 | ||
| 10 | Pancreas | 1000 | Pancreas | C25.0-C25.9 | Lymphomas | M9590-9989 |
| 11 | Other digestive system | 1101 | Retroperitoneum | C48.0 | Lymphomas | M9590-9989 |
| 1102 | Peritoneum, omentum,and mesentery | C48.1-C48.2 | Lymphomas | M9590-9989 | ||
| 1103 | Other digestive organs | C26.8-C26.9, C48.8 | Lymphomas | M9590-9989 | ||
| 12 | Larynx | 1200 | Larynx | C32.0-C32.9 | Lymphomas | M9590-9989 |
| 13 | Lung and bronchus | 1300 | Lung and bronchus | C34.0-C34.9 | Lymphomas | M9590-9989 |
| 14 | Other respiratory system | 1401 | Nasal cavity and middle ear | C30.0-C30.1 | Lymphomas | M9590-9989 |
| 1402 | Pleura | C38.4 | Lymphomas | M9590-9989 | ||
| 1403 | Trachea, mediastinum, and other respiratory organs | C33.9, C38.1-C38.3, C38.8, C39.0, C39.8, C39.9 | Lymphomas | M9590-9989 | ||
| 15 | Bones and joints | 1500 | Bones and joints | C40.0-C41.9 | Lymphomas | M9590-9989 |
| 16 | Soft tissues (including heart) | 1600 | Soft tissues (including heart) | C38.0, C47.0- C47.9, C49.0-C49.9 | Lymphomas | M9590-9989 |
| 17 | Cutaneous melanoma | 1701 | In Situ Cutaneous melanoma | C44.0-C44.9, M8720-M8790 (ICD-O-3 Behavior = 2) | - | - |
| 1702 | Invasive Cutaneous melanoma | C44.0-C44.9, M8720-M8790 (ICD-O-3 Behavior = 3) | - | - | ||
| 18 | Other non-melanoma skin, excluding basal and squamous cell carcinoma | 1800 | Other non-melanoma skin, excluding basal and squamous cell carcinoma | C44.0-C44.9 (ICD-O-3 Behavior = 3) | - | M-8000:800 5, M-8010:8045, M-8050:808 4, M-8090:8110, M-8720:8790, M9590-9989 |
| 19 | Breast | 1900 | Breast | C50.0-C50.9 | Lymphomas | M9590-9989 |
| 20 | Cervix | 2000 | Cervix | C53.0-C53.9 | Lymphomas | M9590-9989 |
| 21 | Uterus | 2101 | Corpus uteri | C54.0-C54.9 | Lymphomas | M9590-9989 |
| 2102 | Uterus, NOS | C55.9 | Lymphomas | M9590-9989 | ||
| 22 | Ovary | 2200 | Ovary | C56.9 | Lymphomas | M9590-9989 |
| 23 | Other female genital | 2301 | Vagina | CC52.9 | Lymphomas | M9590-9989 |
| 2302 | Vulva | C51.0-C51.9 | Lymphomas | M9590-9989 | ||
| 2303 | Other female genital | C57.0-C58.9 | Lymphomas | M9590-9989 | ||
| 24 | Prostate | 2400 | Prostate | C61.9 | Lymphomas | M9590-9989 |
| 25 | Testis | 2500 | Testis | C62.0-C62.9 | Lymphomas | M9590-9989 |
| 26 | Other male genital | 2601 | Penis | C60.0-C60.9 | Lymphomas | M9590-9989 |
| 2602 | Other male genital | C63.0-C63.9 | Lymphomas | M9590-9989 | ||
| 27 | Bladder | 2701 | Bladder - In Situ | C67.0-C67.9 (ICD-O-3 Behavior = 2) | Lymphomas | M9590-9989 |
| 2701 | Bladder - Malignant | C67.0-C67.9 (ICD-O-3 Behavior = 3) | Lymphomas | M9590-9989 | ||
| 28 | Kidney and renal pelvis | 2800 | Kidney and renal pelvis | C64.9, C65.9 | Lymphomas | M9590-9989 |
| 29 | Other urinary | 2900 | Ureter | C66.9 | Lymphomas | M9590-9989 |
| Other urinary | 68.0-C68.9 | Lymphomas | M9590-9989 | |||
| 30 | Eye and orbit | 3000 | Eye and orbit | C69.0-C69.9 | Lymphomas | M9590-9989 |
| 31 | Brain | 3100 | Brain | C71.0-C71.9 | Meningiomas | M-9530:9539 |
| Lymphomas | M9590-9989 | |||||
| 32 | Other central nervous system | 3200 | Other central nervous system | C71.0-C71.9 (M9530-9539), C70.0-C70.9, C72.0-C72.9 | Lymphomas | M9590-9989 |
| 33 | Thyroid | 3300 | Thyroid | C73.9 | Lymphomas | M9590-9989 |
| 34 | Other endocrine | 3400 | Thymus | C37.9 | Lymphomas | M9590-9989 |
| Adrenal gland | C74.0-C74.9 | Lymphomas | M9590-9989 | |||
| Other endocrine | C75.0-C75.9 | Lymphomas | M9590-9989 | |||
| 35 | Hodgkin's lymphoma | 3500 | Hodgkin's lymphoma | (All Sites) M9650-M9667 | - | - |
| 36 | Non-Hodgkin's lymphoma | 3600 | Non-Hodgkin's lymphoma | (All Sites) M9590-959 6, M9670-971 9, M9727-9729 (All Sites EXCEPT C024, C098-C099, C111, C142, C379, C420-C422, C424, C770-C779) M9823, M9827 | - | - |
| 37 | Multiple myeloma | 3700 | Multiple myeloma | M9731-9732, M9734 | - | - |
| 38 | Lymphocytic leukemia | 3801 | Acute lymphocytic | (All Sites) M9826, M9835-M9837 | - | - |
| 3802 | Chronic lymphocytic | (Sites C420, C421, C424)M9823 | - | - | ||
| 3803 | Other lymphocytic | M9820, M9832-M9834, M9940 | - | - | ||
| 39 | Myeloid leukemia | 3901 | Acute Myeloid | M9840,M9861, M9866,M9867, M9871-9874, M9895-M9897, M9910, M9920 | - | - |
| 3902 | Chronic Myeloid | M9863, M9875, M9876, M9945, M9946 | - | - | ||
| 3903 | Other Myeloid | M9860, M9930 | - | - | ||
| 40 | Monocytic leukemia | 4001 | Acute monocytic | M9891 | - | - |
| 4002 | (No longer valid in ICD-O-3) | - | - | |||
| (No longer valid in ICD-O-3) | - | - | ||||
| 41 | Other leukemia | 4101 | Other acute | M9801, M9805, M9931 | - | - |
| (No longer valid in ICD-O-3) | - | - | ||||
| 4103 | Aleukemic, subleukemic and NOS | (All Sites) M9733, M9742, M9800, M9831, M9870, M9948, M9963, M9964 (Sites C420, C421, C424) M9827 | - | - | ||
| 42 | Other sites/types (not specified above) | 4200 | (No longer valid in ICD-O-3) | - | - | |
| Mast cell tumors | M9740-M9741 | - | - | |||
| Histiocytes and Accessory Lymphoid Cells | M9750-M9758 | - | - | |||
| Immuno-proliferative Diseases | M9760-M976 9 | - | - | |||
| Miscellaneous myeloproliferative and lympho-proliferative disorders | M9950-9989 | - | - | |||
| Other and ill-defined sites | (SitesC76.0-C76.8 ) M8000-M9589 | - | - | |||
| Cancers of unknown primary sites | C80.9(M8000:9589) | - | - | |||
| Other cancers of the hematopoietic and reticuloendothelial systems | C42.0-C42.4(M8000:9589) | - | - | |||
| Other cancers of the lymph nodes | C77.0-C77.9(M8000:9589) | - | - |